222 related articles for article (PubMed ID: 12895683)
1. Salvia for dementia therapy: review of pharmacological activity and pilot tolerability clinical trial.
Perry NS; Bollen C; Perry EK; Ballard C
Pharmacol Biochem Behav; 2003 Jun; 75(3):651-9. PubMed ID: 12895683
[TBL] [Abstract][Full Text] [Related]
2. In-vitro activity of S. lavandulaefolia (Spanish sage) relevant to treatment of Alzheimer's disease.
Perry NS; Houghton PJ; Sampson J; Theobald AE; Hart S; Lis-Balchin M; Hoult JR; Evans P; Jenner P; Milligan S; Perry EK
J Pharm Pharmacol; 2001 Oct; 53(10):1347-56. PubMed ID: 11697542
[TBL] [Abstract][Full Text] [Related]
3. Butyryl- and acetyl-cholinesterase inhibitory activities in essential oils of Salvia species and their constituents.
Savelev SU; Okello EJ; Perry EK
Phytother Res; 2004 Apr; 18(4):315-24. PubMed ID: 15162368
[TBL] [Abstract][Full Text] [Related]
4. Monoterpenoid extract of sage (Salvia lavandulaefolia) with cholinesterase inhibiting properties improves cognitive performance and mood in healthy adults.
Kennedy DO; Dodd FL; Robertson BC; Okello EJ; Reay JL; Scholey AB; Haskell CF
J Psychopharmacol; 2011 Aug; 25(8):1088-100. PubMed ID: 20937617
[TBL] [Abstract][Full Text] [Related]
5. In-vitro inhibition of human erythrocyte acetylcholinesterase by salvia lavandulaefolia essential oil and constituent terpenes.
Perry NS; Houghton PJ; Theobald A; Jenner P; Perry EK
J Pharm Pharmacol; 2000 Jul; 52(7):895-902. PubMed ID: 10933142
[TBL] [Abstract][Full Text] [Related]
6. Acetylcholinesterase inhibitors from plants.
Mukherjee PK; Kumar V; Mal M; Houghton PJ
Phytomedicine; 2007 Apr; 14(4):289-300. PubMed ID: 17346955
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory activities of major anthraquinones and other constituents from Cassia obtusifolia against β-secretase and cholinesterases.
Jung HA; Ali MY; Jung HJ; Jeong HO; Chung HY; Choi JS
J Ethnopharmacol; 2016 Sep; 191():152-160. PubMed ID: 27321278
[TBL] [Abstract][Full Text] [Related]
8. Systematic review of clinical trials assessing pharmacological properties of Salvia species on memory, cognitive impairment and Alzheimer's disease.
Miroddi M; Navarra M; Quattropani MC; Calapai F; Gangemi S; Calapai G
CNS Neurosci Ther; 2014 Jun; 20(6):485-95. PubMed ID: 24836739
[TBL] [Abstract][Full Text] [Related]
9. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
Wilkinson DG; Francis PT; Schwam E; Payne-Parrish J
Drugs Aging; 2004; 21(7):453-78. PubMed ID: 15132713
[TBL] [Abstract][Full Text] [Related]
10. A new lupene triterpenetriol and anticholinesterase activity of Salvia sclareoides.
Rauter AP; Branco I; Lopes RG; Justino J; Silva FV; Noronha JP; Cabrita EJ; Brouard I; Bermejo J
Fitoterapia; 2007 Dec; 78(7-8):474-81. PubMed ID: 17570616
[TBL] [Abstract][Full Text] [Related]
11. Phytochemical profiling and in vitro screening for anticholinesterase, antioxidant, antiglucosidase and neuroprotective effect of three traditional medicinal plants for Alzheimer's Disease and Diabetes Mellitus dual therapy.
Penumala M; Zinka RB; Shaik JB; Mallepalli SKR; Vadde R; Amooru DG
BMC Complement Altern Med; 2018 Mar; 18(1):77. PubMed ID: 29499679
[TBL] [Abstract][Full Text] [Related]
12. Cholinesterase Inhibitor Therapy in Alzheimer's Disease: The Limits and Tolerability of Irreversible CNS-Selective Acetylcholinesterase Inhibition in Primates.
Moss DE; Perez RG; Kobayashi H
J Alzheimers Dis; 2017; 55(3):1285-1294. PubMed ID: 27858711
[TBL] [Abstract][Full Text] [Related]
13. Molecular recognition of rosmarinic acid from Salvia sclareoides extracts by acetylcholinesterase: a new binding site detected by NMR spectroscopy.
Marcelo F; Dias C; Martins A; Madeira PJ; Jorge T; Florêncio MH; Cañada FJ; Cabrita EJ; Jiménez-Barbero J; Rauter AP
Chemistry; 2013 May; 19(21):6641-9. PubMed ID: 23536497
[TBL] [Abstract][Full Text] [Related]
14. Effect of some medicinal plant extracts on the oxidative stress status in Alzheimer's disease induced in rats.
Mahdy K; Shaker O; Wafay H; Nassar Y; Hassan H; Hussein A
Eur Rev Med Pharmacol Sci; 2012 Jul; 16 Suppl 3():31-42. PubMed ID: 22957416
[TBL] [Abstract][Full Text] [Related]
15. Long-lasting acetylcholinesterase splice variations in anticholinesterase-treated Alzheimer's disease patients.
Darreh-Shori T; Hellström-Lindahl E; Flores-Flores C; Guan ZZ; Soreq H; Nordberg A
J Neurochem; 2004 Mar; 88(5):1102-13. PubMed ID: 15009666
[TBL] [Abstract][Full Text] [Related]
16. Targeting acetylcholinesterase and butyrylcholinesterase in dementia.
Lane RM; Potkin SG; Enz A
Int J Neuropsychopharmacol; 2006 Feb; 9(1):101-24. PubMed ID: 16083515
[TBL] [Abstract][Full Text] [Related]
17. Cryptotanshinone, an acetylcholinesterase inhibitor from Salvia miltiorrhiza, ameliorates scopolamine-induced amnesia in Morris water maze task.
Wong KK; Ho MT; Lin HQ; Lau KF; Rudd JA; Chung RC; Fung KP; Shaw PC; Wan DC
Planta Med; 2010 Feb; 76(3):228-34. PubMed ID: 19774505
[TBL] [Abstract][Full Text] [Related]
18. From traditional European medicine to discovery of new drug candidates for the treatment of dementia and Alzheimer's disease: acetylcholinesterase inhibitors.
Russo P; Frustaci A; Del Bufalo A; Fini M; Cesario A
Curr Med Chem; 2013; 20(8):976-83. PubMed ID: 23210783
[TBL] [Abstract][Full Text] [Related]
19. Novel diterpenoid acetylcholinesterase inhibitors from Salvia miltiorhiza.
Ren Y; Houghton PJ; Hider RC; Howes MJ
Planta Med; 2004 Mar; 70(3):201-4. PubMed ID: 15114495
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
